These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2272174)

  • 21. Mutations and expression of the ras family genes in leukemias.
    Gougopoulou DM; Kiaris H; Ergazaki M; Anagnostopoulos NI; Grigoraki V; Spandidos DA
    Stem Cells; 1996 Nov; 14(6):725-9. PubMed ID: 8948029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
    Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
    Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of ras mutation in myelodysplastic syndrome.
    Yunis JJ; Boot AJ; Mayer MG; Bos JL
    Oncogene; 1989 May; 4(5):609-14. PubMed ID: 2657575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetic biomarkers in myeloid malignancies.
    Matynia AP; Szankasi P; Shen W; Kelley TW
    Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis of gene rearrangements and mutations in acute leukemias and myeloproliferative neoplasms.
    Sholl LM; Longtine J
    Curr Protoc Hum Genet; 2010 Oct; Chapter 10():Unit 10.4. PubMed ID: 20891029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNMT3A mutations in myeloproliferative neoplasms.
    Stegelmann F; Bullinger L; Schlenk RF; Paschka P; Griesshammer M; Blersch C; Kuhn S; Schauer S; Döhner H; Döhner K
    Leukemia; 2011 Jul; 25(7):1217-9. PubMed ID: 21537334
    [No Abstract]   [Full Text] [Related]  

  • 29. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases.
    Voso MT; Fabiani E; Fianchi L; Falconi G; Criscuolo M; Santangelo R; Chiusolo P; Betti S; D'Alo' F; Hohaus S; De Stefano V; Leone G
    Leukemia; 2013 Apr; 27(4):982-5. PubMed ID: 22964944
    [No Abstract]   [Full Text] [Related]  

  • 30. Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms.
    Rotunno G; Guglielmelli P; Biamonte F; Rumi E; Cazzola M; Vannucchi AM
    Ann Hematol; 2014 Mar; 93(3):523-4. PubMed ID: 23793880
    [No Abstract]   [Full Text] [Related]  

  • 31. Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.
    Chan IT; Gilliland DG
    Cell Cycle; 2004 May; 3(5):536-7. PubMed ID: 15020845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations of the ras proto-oncogenes in childhood monosomy 7.
    Neubauer A; Shannon K; Liu E
    Blood; 1991 Feb; 77(3):594-8. PubMed ID: 1991170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML).
    Owen C
    Leuk Res; 2010 Feb; 34(2):141-2. PubMed ID: 19695705
    [No Abstract]   [Full Text] [Related]  

  • 34. Loss of multiple point mutations of RAS genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome.
    Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakao Y; Fujita T
    Br J Haematol; 1991 Feb; 77(2):250-2. PubMed ID: 2004029
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
    Kim T; Ahn JS; Son MH; Novitzky-Basso I; Yi SY; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Moon JH; Sohn SK; Kim HJ; Zhang Z; Kim DDH
    Leuk Res; 2022 Jul; 118():106858. PubMed ID: 35609360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.
    Gómez-Seguí I; Makishima H; Jerez A; Yoshida K; Przychodzen B; Miyano S; Shiraishi Y; Husseinzadeh HD; Guinta K; Clemente M; Hosono N; McDevitt MA; Moliterno AR; Sekeres MA; Ogawa S; Maciejewski JP
    Leukemia; 2013 Sep; 27(9):1943-6. PubMed ID: 23765226
    [No Abstract]   [Full Text] [Related]  

  • 37. [Overview--Recent therapeutic strategy for hematologic disorders of bone marrow].
    Inokuchi K
    Rinsho Ketsueki; 2014 Jan; 55(1):29-30. PubMed ID: 24492034
    [No Abstract]   [Full Text] [Related]  

  • 38. RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia.
    Kelemen K; Kovacsovics T; Braziel R; Corless C; Beadling C; Fan G
    Leuk Lymphoma; 2012 May; 53(5):999-1002. PubMed ID: 22035377
    [No Abstract]   [Full Text] [Related]  

  • 39. Cancer predisposition syndromes associated with myeloid malignancy.
    Quinn E; Nichols KE
    Semin Hematol; 2017 Apr; 54(2):115-122. PubMed ID: 28637615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Approach to diagnosis and management of myeloproliferative neoplasm variants].
    Mitsumori T; Kirito K
    Rinsho Ketsueki; 2015 Aug; 56(8):963-71. PubMed ID: 26345554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.